Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach.
Fiche publication
Date publication
octobre 2019
Journal
Journal of clinical medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LESSINGER Jean-Marc
Tous les auteurs :
Nazon C, Sabo AN, Becker G, Lessinger JM, Kemmel V, Paillard C
Lien Pubmed
Résumé
Hydroxyurea (HU) is a FDA- and EMA-approved drug that earned an important place in the treatment of patients with severe sickle cell anemia (SCA) by showing its efficacy in many studies. This medication is still underused due to fears of physicians and families and must be optimized.
Mots clés
hydroxyurea, pharmacokinetics, sickle cell anemia, sickle cell disease
Référence
J Clin Med. 2019 Oct 16;8(10):